

8<sup>th</sup> Canadian Kidney Cancer Forum

# Canadian Kidney Cancer Forum

FINAL PROGRAM

#CKCF17

February 2-4, 2017

The Westin Toronto Airport, Toronto, ON

# 8<sup>th</sup> Canadian Kidney Cancer Forum

## Objectives for Forum 2017

The primary meeting objectives are to:

- Increase knowledge of recent developments in the management of renal cell carcinoma;
- Discuss and stimulate new research in kidney cancer nationally;
- Raise awareness of ongoing research in kidney cancer in Canada;
- Identify future initiatives and projects for the KCRNC;
- Explore ideas to ensure the progress and sustainability of KCRNC;
- Examine recent clinical trial data.

### THURSDAY, FEBRUARY 2, 2017

1300 - 1800      [Arrival & Registration - Sutton Foyer](#)

1830 - 1930      [Buffet Dinner - Sutton C](#)

### SESSION I - [Sutton B](#)

1930 - 1935      [Introduction of Program Chairs](#)  
Anil Kapoor

1935 - 1945      [Welcome](#)  
Christian Kollmannsberger, Alan So

*Introduction/Moderator: Aaron Hansen, Princess Margaret Cancer Centre*

1945 - 2015      [Keynote Lecture: The Evolution of Immunotherapy: Past and Present](#)  
Hans Hammers

# 8<sup>th</sup> Canadian Kidney Cancer Forum

Introduction/Moderator: Antonio Finelli, *University of Toronto* & Scott North, *University of Alberta*

2015 - 2100      Science Roundtable – Presentations of Current Research

- Patient Derived Xenografts of Metastatic Renal Cell Carcinoma to Guide Dose Escalation Regimens and Drug Matching  
Matthew Lowerison
- Baseline Edmonton Symptom Assessment Scale (ESAS) and Survival in Metastatic Renal Cell Carcinoma (mRCC)  
Jeffrey Graham
- Genetic Testing for Hereditary Renal Cancer in Ontario: A Preliminary Retrospective Review  
Melanie Care
- Y-Box Binding Protein 1 is Crucial in Acquiring Drug Resistance in Advanced Renal Cell Carcinoma  
Ninadh D'Costa

2100 - 2300      Networking in Hospitality Suite – All Welcome - [Suite 1115](#)  
(Anil Kapoor)

## FRIDAY, FEBRUARY 3, 2017

0700 - 0830      [Buffet Breakfast - Sutton A](#)

0800 - 0900      CKCis Operations Committee Meeting  
(By invitation to CKCis site investigators & staff)  
[- Sutton C](#)

## SESSION II - [Sutton B](#)

Introduction/Moderator: Darrell Drachenberg, *University of Manitoba*

0900 - 0930      Keynote Lecture: Radical Nephrectomy for Select Masses Amenable to Nephron Sparing Surgery: Therapeutic Heresy or Voice of Reason?  
Alexander Kutikov

February 2-4, 2017 • The Westin Toronto Airport, Toronto, ON

# 8<sup>th</sup> Canadian Kidney Cancer Forum

0930 - 1000      Discussion: Future of Canadian Kidney Cancer Surgical Trials  
Michael Jewett, Ricardo Rendon

Introduction/Moderator: Lori Wood, *Dalhousie University*

1000 - 1030      Blind Fight or Are We Any Closer to Develop Predictive Biomarkers for Response  
Sumanta Pal

1030 - 1100      [Break \(Group Photo in Foyer\) - Sutton A](#)

## SESSION III - [Sutton B](#)

Introduction/Moderator: Anand Swaminath & Bobby Shayegan, *McMaster University*

1100 - 1145      Oligometastatic Debate: Role of SBRT vs. Role of Surgery  
Patrick Cheung, Wes Kassouf

Introduction/Moderator: Sebastian Hotte, *McMaster University*

1145 - 1215      Keynote Lecture: Immunotherapy - Ongoing Trials / Combination Therapy: Where are We Going from Here?  
Hans Hammers

1215 - 1245      Discussion: Canadian Clinical Trials Discussion (I/O+ Combo): What to Prioritize?  
Anil Kapoor, Georg Bjarnason

1245 - 1345      [Buffet Lunch - Sutton A](#)

## SESSION IV - [Sutton B](#)

Introduction/Moderator: Christina Canil, *Ottawa University*

1345 - 1415      National Kidney Cancer Patient and Caregiver Survey  
Jennifer Jones, Heather Chappell

# 8<sup>th</sup> Canadian Kidney Cancer Forum

Introduction/Moderator: François Patenaude, *McGill University*

1415 - 1445      Keynote Lecture: Non Clear Cell - Where Are We Now?  
Sumanta Pal

Introduction/Moderator: Piotr Czaykowski, *University of Manitoba*

1445 - 1515      Germ Line Mutations  
Raymond Kim

1515 - 1545      Break - Sutton A

## SESSION V - Sutton B

Introduction/Moderator: Alan So, *University of British Columbia*

1545 - 1615      Genomics in RCC - cfDNA and Tumor DNA Sequencing  
Alex Wyatt

1615 - 1630      Update Dragon's Den project: Integrative Sequencing  
In Germline and Hereditary Tumours (INSIGHT) in  
Non-Clear Cell RCC  
Raymond Kim

Introduction/Moderator: Denis Soulières, *L'Université de Montréal*

1630 - 1700      Keynote Lecture: Adjuvant Treatment - A New  
Standard of Care and Implications on Subsequent  
Therapies?  
Thomas Powles

1700 - 1730      Consensus Discussion: Role of Adjuvant Therapy Post  
Resection of High Risk For Recurrence RCC (*by invitation*)  
- Bristol A  
Pierre Karakiewicz

1900 - 1930      Mix & Mingle: Cocktail Reception - Sutton C Foyer

1930              Banquet Dinner: Peter Venner, Speaker - Sutton C

2100 - 2300      Networking in Hospitality Suite - All Welcome - Suite 1115  
(Anil Kapoor)

# 8<sup>th</sup> Canadian Kidney Cancer Forum

**SATURDAY, FEBRUARY 4, 2017**

0730 - 0830     [Buffet Breakfast - Sutton A](#)

0800 - 0900     [mRCC Consensus Guideline \(by invitation\) - Bristol A](#)  
Neal Reaume

## [SESSION VI - Sutton B](#)

*Introduction/Moderator: Michael Jewett, University of Toronto;  
Ilias Cagiannos, University of Ottawa (CUASF); Christine Collins,  
Kidney Cancer Canada*

### [KCRNC-KCC-CUASF Research Grant Presentations](#)

0900 - 0915     Chromosomal Instability in Cell-Free DNA as Plasma  
Biomarkers for Renal Cell Carcinoma  
George Yousef

0915 - 0930     Exploiting Novel Therapeutic Targets to Block Metastasis  
of Clear Cell Renal Cell Carcinoma  
Jan Rudzinski

0930 - 0945     Predictive RadiOMics Signature for Treatment Response  
to Nivolumab or PD-1/PD-L1 Inhibitors in Patients with  
Advanced Renal Cell Carcinoma (PROMISE)  
Hao-Wen Sim

0945 - 1000     Identification of Predictive Biomarkers in Patients with  
Metastatic Kidney Cancer Using Circulating Tumor DNA  
Sequencing  
Lucia Nappi

1000 - 1015     Development of a Novel Immunotherapeutic Bi-specific  
T-cell Engager Strategy for Renal Cell Carcinoma  
Keith Lawson

1020 - 1045     [Break - Sutton A](#)

# 8<sup>th</sup> Canadian Kidney Cancer Forum

## SESSION VII - Sutton B

Moderator: Robert Sabbagh , *L'Université de Sherbrooke*

1045 - 1100      Update Dragon's Den Project: Small Renal Mass Biopsy  
Tony Finelli

1100 - 1130      Keynote Lecture: Surgery of Localized Kidney Cancer:  
Is a Chance to Cut a Chance to Cure?  
Alexander Kutikov

Introduction/Moderator: Christian Kollmannsberger, *University of British Columbia*

1130 - 1200      Keynote Lecture: The Changing Landscape of mRCC  
Thomas Powles

1200 - 1215      Award Grants and Concluding Statements  
Anil Kapoor, Christian Kollmannsberger, Alan So

1215 - 1000      Consensus Discussion: The Role of LND in Localized mRCC  
(*by invitation*) - [Bristol A](#)  
Alan So

1215              [Boxed Lunch - Sutton A](#)

## SUPPORTED BY

KCRNC  
RRCRC

KIDNEY CANCER RESEARCH  
NETWORK OF CANADA  
RÉSEAU DE RECHERCHE SUR LE  
CANCER DU REIN DU CANADA



February 2-4, 2017 • The Westin Toronto Airport, Toronto, ON

# BIOGRAPHIES

## Meeting Co-Chairs



**Christian Kollmannsberger, MD, FRCPC**

Christian Kollmannsberger, MD, FRCPC, is staff medical oncologist at the British Columbia Cancer Agency (BCCA) Vancouver Cancer Centre and clinical professor at the University of British Columbia. Dr. Kollmannsberger trained in Germany before coming to Canada in 2004.

Nationally and internationally, he has contributed to numerous trials in the field of renal cell carcinoma and testicular cancer. His research focuses on genito-urinary malignancies with a special interest in testicular and renal cell cancer. This includes phase I, II and III clinical trials, the development of new therapeutic options and investigation of mechanisms of treatment resistance.

Currently, Dr. Kollmannsberger serves as chair of the BC Cancer Agency Genitourinary Cancers Systemic Therapy Group, Chair for the Genitourinary and Phase I Clinical Trials Unit at the BC Cancer Agency - Vancouver Centre, chair for the National Cancer Institute of Canada Testis Cancer Disease Oriented Group, and is a member of the National Cancer Institute of Canada Kidney Cancer Disease Oriented Group.

His research has been published in peer-reviewed journals that include the Journal of Clinical Oncology, Clinical Cancer Research, Annals of Oncology, the European Journal of Cancer, Cancer and the British Journal of Cancer. He has served as faculty for international conferences such as the annual meeting of the American Society of Clinical Oncology (ASCO), the ASCO Genitourinary Cancers Symposium, the Annual Meeting of the European Society of Medical Oncology (ESMO), and the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research symposium on "Molecular Targets and Cancer Therapeutics".



# BIOGRAPHIES

## Meeting Co-Chairs



**Alan So**

A graduate of the University of Alberta, Dr. So came to the Vancouver Prostate Centre as a Clinical Fellow in 2002, following completion of his residency at Dalhousie University. Dr. So's current research focuses on the study of development of novel therapeutics for bladder cancer and determination of the functional role of GLI1/2 in the progression of prostate cancer to its lethal stage of androgen independence. He has characterized the functional role of different survival genes (including clusterin and Hsp27) in different tumor models (prostate, breast, lung, and bladder) in cancer progression. His current research focuses on discovery and development of novel agents to treat bladder cancer as well as development of the mechanisms of treatment resistance in renal cell carcinoma.

He is active in clinical trials across Canada and is a member of National Cancer Institute of Canada GU Clinical Trials Group and Canadian Uro-Oncology Group. Currently, he leads the Clinical Trials Unit at the Vancouver Prostate Cancer and is the Chair of the GU Tumour Group at the BC Cancer Agency.

# BIOGRAPHIES

## Canadian Faculty



**Patrick Cheung**

Dr. Patrick Cheung is a Radiation Oncologist from Sunnybrook Odette Cancer Centre specializing in genito-urinary and lung malignancies. He is an Associate Professor in the Department of Radiation Oncology at the University of Toronto. His clinical and research interests revolve around the use of hypofractionated/stereotactic body radiotherapy in the treatment of primary and oligometastatic/oligoprogressive tumours.

---



**Wassim Kassouf**

Dr. Kassouf completed a clinical and research fellowship in urologic oncology at M. D. Anderson Cancer Center in Houston, Texas following medical school and urology residency at McGill University. He then arrived back on faculty at the McGill University Health Centre in 2006. Dr. Kassouf's clinical practice focuses on all aspects of urologic oncology, whereas his research focuses on biology and therapy for bladder cancer. Presently, he is the Program Director of the McGill

Urology Residency. He has led several national guidelines for optimizing quality of care in urologic cancer management and has published over 260 peer-reviewed manuscripts and book chapters. He has obtained independent peer-reviewed grant funding from the CRS and CIHR. He is an associate editor for BMC Urology and is on the editorial board of *Urology*, *CUAJ*, *Clinical Cancer Investigation Journal*, and *International Brazilian Journal of Urology*. He is a course director on bladder and upper tract cancers at the SIU and AUA. He is the founder of the national Canadian Bladder Cancer Network, a cofounder of Bladder Cancer Canada, co-chair of the National Cancer Institute of Canada's disease-oriented group in bladder cancer, and an executive member of the NIH Genitourinary steering committee Bladder Cancer Task Force. Dr. Kassouf is a graduate of the AUA Leadership Program and received several awards, including the AUA Young Urologist of the Year, AUA Research Scholar Award, CUA Scholarship Award, FRSQ Clinician Scientist Research Scholar Award, and the Everett C. Reid Teaching Excellence Award.

# BIOGRAPHIES

## Canadian Faculty



**Raymond Kim**

Raymond Kim, MD/PhD, FRCPC, FCCMG, FACMG is a medical geneticist at Princess Margaret Cancer Centre. He completed his training in Internal Medicine at the University of Toronto, and a fellowship in medical genetics at the Hospital for Sick Children. Clinically he attends a variety of cancer genetics clinics, seeing both adults and children, with a particular emphasis on transition of care and multi-disciplinary models. His research interests lie in the use of novel molecular genetic analyses in patients care and its application in research studies. This includes whole exome sequencing, and whole genome sequencing in high-risk pedigrees and tumours.

---



**Alexander Wyatt**

Dr. Alexander Wyatt is an Assistant Professor at the University of British Columbia and a Senior Research Scientist at the Vancouver Prostate Centre. He has a background in molecular biology and human disease genetics from the University of Oxford, as well as experience in cancer bioinformatics and the analysis of complex datasets. Dr. Wyatt has a strong academic history in translational cancer genomics and his current research is focused on understanding and targeting the molecular landscape of castration-resistance prostate cancer. His lab leverages a variety of innovative next-generation sequencing techniques to interrogate tissue and liquid biopsies from patients enrolled on several ongoing clinical trials. He has been the recipient of multiple awards including a prestigious Coalition to Cure Prostate Cancer Young Investigator Award from the Prostate Cancer Foundation and a Movember Rising Star in Prostate Cancer Research Award from Prostate Cancer Canada.

# BIOGRAPHIES

## International Faculty



**Hans Hammers**

Hans Hammers, M.D., Ph.D. received his M.D. and Ph.D. degrees from the University of Lubeck in Germany. He completed his residency training in the Johns Hopkins medical system and completed his fellowship in Medical Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital. He was leading the kidney cancer research efforts at Johns Hopkins as an Assistant Professor at Johns Hopkins and has contributed greatly to the development of immunotherapy with immune checkpoint inhibitors in kidney cancer. His work in immunotherapy has been nationally recognized and he has been the principal investigators on several industry and investigator sponsored trials. Dr. Hammers was recently recruited to join the leadership of the KCP. In June of 2016, Dr. Hammers joined the faculty at UT Southwestern, where he is Associate Professor in the Department of Internal Medicine and Co-Leader of Clinical Research and Immunotherapy of the KCP. His research interest is in developing novel immunotherapies for kidney cancer. Dr. Hammers is the inaugural recipient of the Eugene P. Frenkel Scholar Award.

---



**Alexander Kutikov**

Dr. Kutikov is an Associate Professor of Surgical Oncology at the Fox Chase Cancer Center. He is a board certified, academic urologic surgical oncologist who treats urologic tumors using minimally invasive (robotic/laparoscopic) and traditional surgical techniques. Alexander has co-authored more than 150 original manuscripts in peer-reviewed journals. He has published chapters in leading textbooks, including the definitive chapter on adrenal disorders in "Campbell-Walsh Urology," and has held leadership positions both in the American College of Surgeons and the American Urological Association. Dr. Kutikov has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care. He is a co-founder of several ventures and currently serves as the Associate Editor for Digital Media for European Urology "Platinum" Journal.

Dr. Kutikov received an MD from Harvard Medical School's Harvard-MIT Health Sciences and Technology Program. He completed Urologic residency training at the University of Pennsylvania and finished a 2-year Society of Urologic Oncology fellowship at the Fox Chase Cancer Center in Philadelphia, USA.

# BIOGRAPHIES

## International Faculty




### Sumanta Kumar Pal

Sumanta Kumar Pal, M.D. is an internationally recognized leader in the area of genitourinary cancers. He is the Co-director of City of Hope's Kidney Cancer Program and head of the kidney and bladder cancer disease team at the institution.

Dr. Pal entered medical school at UCLA at the age of 17, and after completing his residency training, completed a fellowship program in medical oncology at City of Hope where he remains on faculty since 2009. To date, he has published over 150 peer-reviewed articles in prominent journals including *The Journal of Clinical Oncology*, *Lancet Oncology*, and *European Urology*.

Dr. Pal holds patents for new prostate cancer drugs currently under development and maintains one of the largest portfolios of clinical trials for kidney and bladder cancer research on the west coast. He developed an integrated program that focuses on collaborative research across multiple departments including the Beckman Research Institute and Department of Surgery to discover novel therapeutic approaches. He works to push the boundaries of personalized medicine, with several seminal publications that describe unique therapeutic targets in rare genitourinary cancers. He has received grants from the National Institute of Health and multiple other leading entities in support of his formidable research.



### Thomas Powles

Thomas Powles is the director of Barts Cancer centre and the professor of urology Cancer at Barts Cancer Institute. He is the renal cancer oncology lead for London Cancer. He has written 200 peer review publications, writes international guidelines for two cancers and leads 12 prospective clinical studies.

He has been involved in the development of number of immune therapies and leads a translational oncology program in this field. These studies are predominantly in bladder and renal cancer. They include novel combinations and randomised phase 3 studies.

He trained at Imperial college and this thesis focused on overcoming resistance in urology cancer.

# Notes

# Notes

# WE WOULD LIKE TO THANK OUR SPONSORS

## PLATINUM



## GOLD



Bristol-Myers Squibb



NOVARTIS

## BRONZE



EXELIXIS®



MERCK

## CONTRIBUTOR



This meeting has been endorsed by  
the Canadian Urological Association (CUA), February 2017.



Canadian  
Urological  
Association

The *Voice of Urology* in *Canada*

[cua.org](http://cua.org)